ABSTRACT
SETTING: Primary health care unit in Rio de Janeiro City, Brazil. OBJECTIVE: To estimate and compare the cost-effectiveness of strategies used for passive case finding of pulmonary tuberculosis (PTB) cases using tests available at the primary care level. DESIGN: Data on PTB suspects were reviewed, and a decision model was developed using sputum smear microscopy and chest radiography (CXR) according to three different strategies for PTB detection. A cost-effectiveness analysis was performed to estimate the cost per correct PTB diagnosis. Mycobacterial culture was used to calculate the effectiveness of the strategies. Unit costs of health resource utilisation were obtained from the payer's perspective (the Brazilian Public Health System). RESULTS: For the evaluation of 254 PTB suspects, the total costs of strategies ranged from US$5369 to US$5944; the probability of a correct PTB diagnosis ranged from 0.66 to 0.86; the number of visits required to complete the diagnostic process ranged from two to three, and cost per PTB case identified ranged from US$47.93 to US$53.07. The cost-effectiveness of the three strategies studied varied between US$56.69 and US$72.55 per correct PTB case detected. CONCLUSION: A strategy in which sputum smears and CXR were requested for all PTB suspects at the initial evaluation was cost-effective, had a high probability of correct PTB diagnosis and could be accomplished in two visits.
Subject(s)
Bacteriological Techniques/economics , Primary Health Care/economics , Sputum/microbiology , Tuberculosis, Pulmonary/diagnosis , Adult , Aged , Bacteriological Techniques/methods , Brazil , Cost-Benefit Analysis , Female , Health Care Costs , Humans , Male , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Primary Health Care/methods , Retrospective Studies , Tuberculosis, Pulmonary/economics , Young AdultABSTRACT
SETTING: Tuberculosis (TB) clinic of a university-based public hospital in Rio de Janeiro city, Brazil. OBJECTIVE: To describe treatment outcomes for TB patients with liver injury who received a 12-month regimen of ethambutol (E, EMB) and ofloxacin (O, OFL), including streptomycin (S, SM) for the first 3 months (3SEO/9EO) under routine clinical care conditions. DESIGN: A retrospective study of a cohort of TB patients prescribed 3SEO/9EO was conducted over a 66-month period. Data were obtained by review of existing medical records. Primary outcomes assessed were cure, treatment failure, treatment default, TB relapse and death. RESULTS: Outcomes were assessed for 40 patients with hepatic injury who met study criteria. Twenty-three (58%) were male and 13 (33%) were human immunodeficiency virus seropositive. Thirty-four (85%) patients were cured. Three patients (7.5%) defaulted from treatment, and three other patients died (7.5%). There were no treatment failures or relapses during 2 years of follow-up. Clinically recognized drug toxicity occurred in five patients (12.5%), and in each case was attributed to SM. CONCLUSION: In this series of TB patients with serious liver injury, 3SEO/9EO was well-tolerated, and it was effective in 85% of patients when used under routine clinical care conditions.
Subject(s)
Antitubercular Agents/administration & dosage , Liver Diseases/drug therapy , Liver Diseases/epidemiology , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/epidemiology , Antitubercular Agents/adverse effects , Brazil , Cohort Studies , Comorbidity , Confidence Intervals , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Ethambutol/administration & dosage , Ethambutol/adverse effects , Female , Follow-Up Studies , Hospitals, Public , Humans , Liver Diseases/diagnosis , Liver Function Tests , Male , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Odds Ratio , Ofloxacin/administration & dosage , Ofloxacin/adverse effects , Recurrence , Retrospective Studies , Risk Assessment , Severity of Illness Index , Streptomycin/administration & dosage , Streptomycin/adverse effects , Survival Rate , Treatment Failure , Treatment Outcome , Tuberculosis, Pulmonary/diagnosis , Urban PopulationABSTRACT
Patients with a dominant small deletion (818del4, hotspot) in the interferon-gamma receptor 1 (IFNGR1) gene (6q23-q24) and increased susceptibility to mycobacterial infections have been recently reported. We describe a female patient homozygous for a 4-bp deletion in exon 5 of IFNGR1 (561del4) who developed postvaccinal disseminated Bacille Calmette-Guerin infection. She was born to unrelated Argentinean parents, each of whom was heterozygous for this mutation. 561del4 has been previously described as a maternally inherited mutation in a compound heterozygous German patient. By single nucleotide polymorphism analysis of the areas surrounding the deletion, we showed the independent inheritance of 561del4 in three heterozygous carriers. Polypurine runs and "direct repeats," previously shown to be associated with areas of recurrent small deletions, were found in the flanking region of 561del4. The independent inheritance of three identical mutational events defines 561del4 as a new hotspot in the IFNGR1 gene.
Subject(s)
Receptors, Interferon/genetics , Sequence Deletion , BCG Vaccine/adverse effects , Chromosomes, Human, Pair 6 , Exons , Female , Homozygote , Humans , Infant , Introns , Mycobacterium Infections/genetics , Polymorphism, Single Nucleotide , Vaccination/adverse effects , Interferon gamma ReceptorABSTRACT
Interferon-gamma receptor deficiency is a recently described immunodeficiency that is associated with onset of severe mycobacterial infections in childhood. We describe the occurrence of symptomatic and often severe viral infections in 4 patients with interferon-gamma receptor deficiency and mycobacterial disease. The viral pathogens included herpes viruses, parainfluenza virus type 3, and respiratory syncytial virus. We conclude that patients with interferon-gamma receptor deficiency and mycobacterial disease have increased susceptibility to some viral pathogens.
Subject(s)
Mycobacterium Infections/immunology , Receptors, Interferon/deficiency , Virus Diseases/immunology , Antigens, CD/genetics , Child , Child, Preschool , Female , Humans , Immunologic Deficiency Syndromes/genetics , Immunologic Deficiency Syndromes/immunology , Infant , Male , Phenotype , Receptors, Interferon/immunology , Interferon gamma ReceptorABSTRACT
Burkholderia species, notably Burkholderia cepacia and Burkholderia gladioli, are important pathogens in patients with chronic granulomatous disease (CGD). Burkholderia pseudomallei, the causative agent of melioidosis, is endemic in Southeast Asia and northern Australia but is a rare pathogen in other parts of the world. We describe the occurrence of B. pseudomallei infection in a Puerto Rican patient with CGD. This is one of only a small number of documented cases of melioidosis autochthonous to the Americas and is the first reported case of B. pseudomallei infection in a CGD patient from the Americas. We conclude that B. pseudomallei, like B. cepacia and B. gladioli, should be considered a potential pathogen in patients with CGD and that melioidosis should be considered in the differential diagnosis for ill residents of or travelers to Puerto Rico.